ReNeuron Group plc Notification of Interim Results (3245W)

TIDMRENE

RNS Number : 3245W

ReNeuron Group plc

13 November 2017

 
 13 November 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or "the Company")

Notification of Interim Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2017 on Thursday 14 December 2017.

A meeting for analysts will be held at 9.30am on the morning of 14 December 2017 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results:

http://vm.buchanan.uk.com/2017/reneuron141217/registration.htm

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

ENQUIRIES:

 
ReNeuron                                                                  [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                                  [phone] 
Mark Court, Sophie Wills, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                            [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
N+1 Singer Advisory LLP                                                   [phone] 
Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREAFFDFAAXFFF

(END) Dow Jones Newswires

November 13, 2017 06:30 ET (11:30 GMT)